TABLE 1

Tumor Responses in Patients with GEP Tumors and Treated with Various Radiolabeled Somatostatin Analogs

Center (reference)	Ligand	No. of patients	Tumor response
Center (reference)	Ligand	No. of patients				CR*	PR*	MR*	SD*	PD*	CR + PR^†
Rotterdam (2)	[¹¹¹In-DTPA⁰]octreotide	26	0	0	5 (19)	11 (42)	10 (38)	0
New Orleans (3)	[¹¹¹In-DTPA⁰]octreotide	26	0	2 (8)	NA	21 (81)	3 (12)	8
Milan (10)	[⁹⁰Y-DOTA⁰, Tyr³]octreotide	21	0	6 (29)	NA	11 (52)	4 (19)	29
Basel (5,6)	[⁹⁰Y-DOTA⁰, Tyr³]octreotide	74	3 (4)	15 (20)	NA	48 (65)	8 (11)	24
Basel (7)	[⁹⁰Y-DOTA⁰, Tyr³]octreotide	33	2 (6)	9 (27)	NA	19 (57)	3 (9)	33
Rotterdam (11)	[⁹⁰Y-DOTA⁰, Tyr³]octreotide	54	0	4 (7)	7 (13)	33 (61)	10 (19)	7
Rotterdam (18)	[¹⁷⁷Lu-DOTA⁰, Tyr³]octreotate	76	1 (1)	22 (29)	9 (12)	30 (39)	14 (18)	30

↵* Reported as number (percentage) of patients. SD = stable disease; NA = not available.
↵^† Reported as percentage of patients.